Kimberly Butler
About Kimberly Butler
Kimberly Butler is a Senior Member of Technical Staff at Sandia National Laboratories, with extensive experience in nanoscience, nanomedicine, and oncology research.
Title
Kimberly Butler holds the position of Senior Member of Technical Staff at Sandia National Laboratories. She has been with the organization since 2017.
Current Role at Sandia National Laboratories
Kimberly Butler joined Sandia National Laboratories in 2017 as a Senior Member of Technical Staff. At Sandia, she is involved in advanced research and contributes her extensive experience in biochemistry, nanoscience, and nanomedicine. Her work supports the lab's initiatives in developing innovative solutions for national security, energy, and other critical areas.
Previous Positions
Before her current role, Kimberly Butler served as a Faculty Research Assistant Professor at the University of New Mexico from 2015 to 2017, specializing in nanomedicine and working closely with Dr. C. Jeffrey Brinker in the Nanoscience and Nanomedicine Laboratory. She also held the position of Interagency Oncology Taskforce Fellow at the National Cancer Institutes (NCI) from 2011 to 2013, where she worked at the Food and Drug Administration (FDA). Additionally, she served the University of New Mexico School of Medicine as a Postdoctoral Fellow from 2008 to 2011 and a Graduate Research Assistant from 2002 to 2008.
Educational Background
Kimberly Butler earned her PhD in Biomedical Sciences from The University of New Mexico School of Medicine. She also holds a certificate in Clinical and Translational Research from the same institution, obtained between 2010 and 2011. Prior to this, she achieved a Baccalaureate in Biochemistry from Reed College.
Research and Contributions
While at the FDA, Kimberly Butler focused on the interaction of nanoparticles with genotoxicity testing. She acted as a genotoxicity expert in the review of medical device submissions at the Center for Devices and Radiological Health. Additionally, she examined methods of detecting rare mutant DNA using PCR and next-generation sequencing technology.